Abstract
Drug resistance represents a serious barrier to the successful treatment of hematological malignancies. In leukemias, resistance mechanisms that involve membrane-resident proteins belonging to the ABC (ATP-binding cassette) transporter protein family are of particular interest, wherein enhanced expression is often associated with poor prognosis and frequent in relapsed or refractory disease. These proteins reduce the intracellular concentration of antitumor agents, greatly diminishing clinical efficacy. Research in this area has been directed at the design of agents, “pump antagonists”, to overcome the effluxing capacity of drug transporters; however, this direction has had limited clinical success. An allied function of ABC transporters like P-glycoprotein (P-gp) is glycolipid trafficking, an area that has not been explored from a therapeutic standpoint. In this capacity, it turns out that glycolipid synthesis can be attenuated by pump antagonists; this is perhaps an adventitious property of P-gp. Recent research in the area of lipid metabolism, specifically ceramide and glycolipids, has provided insight into the function of glycosphingolipids in multidrug resistance and in the action of chemotherapy. This review is intended to bring together those aspects of glycosphingolipid metabolism that might be leveraged to enhance the therapeutic performance of ceramide and to discuss how ABC transporters like P-gp might be targeted to potentiate and magnify ceramide-driven proapoptotic cascades.
Keywords: Ceramide, drug resistance, glucosylceramide, glucosylceramide synthase, glycosphingolipids, leukemia, P-glycoprotein, sphingolipids, GCS, SMS, TNF, FAS
Anti-Cancer Agents in Medicinal Chemistry
Title: Sphingolipid Metabolism and Drug Resistance in Hematological Malignancies
Volume: 11 Issue: 9
Author(s): Valerie Gouaze-Andersson and Myles C. Cabot
Affiliation:
Keywords: Ceramide, drug resistance, glucosylceramide, glucosylceramide synthase, glycosphingolipids, leukemia, P-glycoprotein, sphingolipids, GCS, SMS, TNF, FAS
Abstract: Drug resistance represents a serious barrier to the successful treatment of hematological malignancies. In leukemias, resistance mechanisms that involve membrane-resident proteins belonging to the ABC (ATP-binding cassette) transporter protein family are of particular interest, wherein enhanced expression is often associated with poor prognosis and frequent in relapsed or refractory disease. These proteins reduce the intracellular concentration of antitumor agents, greatly diminishing clinical efficacy. Research in this area has been directed at the design of agents, “pump antagonists”, to overcome the effluxing capacity of drug transporters; however, this direction has had limited clinical success. An allied function of ABC transporters like P-glycoprotein (P-gp) is glycolipid trafficking, an area that has not been explored from a therapeutic standpoint. In this capacity, it turns out that glycolipid synthesis can be attenuated by pump antagonists; this is perhaps an adventitious property of P-gp. Recent research in the area of lipid metabolism, specifically ceramide and glycolipids, has provided insight into the function of glycosphingolipids in multidrug resistance and in the action of chemotherapy. This review is intended to bring together those aspects of glycosphingolipid metabolism that might be leveraged to enhance the therapeutic performance of ceramide and to discuss how ABC transporters like P-gp might be targeted to potentiate and magnify ceramide-driven proapoptotic cascades.
Export Options
About this article
Cite this article as:
Gouaze-Andersson Valerie and C. Cabot Myles, Sphingolipid Metabolism and Drug Resistance in Hematological Malignancies, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (9) . https://dx.doi.org/10.2174/187152011797655069
DOI https://dx.doi.org/10.2174/187152011797655069 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Resistance in Childhood Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Small Molecule Inhibitors of Stat3 Signaling Pathway
Current Cancer Drug Targets Transition Metal-Based Prodrugs for Anticancer Drug Delivery
Current Medicinal Chemistry The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases
Cardiovascular & Hematological Disorders-Drug Targets Immune Therapy in Pancreatic Cancer: Now and the Future?
Reviews on Recent Clinical Trials Chemistry and Pharmacological Properties of Some Natural and Synthetic Antioxidants for Heavy Metal Toxicity
Current Medicinal Chemistry Reposition of the Fungicide Ciclopirox for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews VEGF Inhibitors and Prostate Cancer Therapy
Current Molecular Pharmacology Epigenetic Modifications in Acute Lymphoblastic Leukemia: From Cellular Mechanisms to Therapeutics
Current Gene Therapy Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Antineovascular Agents in the Treatment of Eye Diseases
Current Pharmaceutical Design Editorial [Hot Topic: Immunotherapy of Cancer (Guest Editors: Ezra E.W. Cohen and Nikolai G. Rainov)]
Reviews on Recent Clinical Trials Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept
Current Cancer Drug Targets Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Emerging Strategies to Strengthen the Anti-Tumour Activity of Type I Interferons: Overcoming Survival Pathways
Current Cancer Drug Targets Optimizing Outcomes Following Allogeneic Hematopoietic Progenitor Cell Transplantation in AML: The Role of Hypomethylating Agents
Current Cancer Drug Targets Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells
Current Drug Targets